Title: Johnson & Johnson (NYSE:JNJ) Increases Dividend and Reports Strong Q1 Earnings Growth
Date: 2025-04-15 17:30
URL: https://finance.yahoo.com/news/johnson-johnson-nyse-jnj-increases-173039383.html?.tsrc=rss

Oops, something went wrong
Tip: Try a valid symbol or a specific company name for relevant results
Oops, something went wrong
The major indexes sank to session lows as Fed Chair Powell warned of stagflationary impacts from President Trump's tariffs.
Powell sees 'challenging scenario' for Fed if Trump tariffs stoke inflation and slow growth
The Nasdaq fell over 2%, leading the way down as Nvidia found itself caught in the crossfire of the US-China trade war.
The Treasury secretary told us he thinks America's biggest CEOs should stop worrying about the economy. Here's why.
The chipmaker's stock took a hit after it revealed the Trump administration's surprise new controls on exports to China.
Stocks resume slide as Nvidia weighs on tech
Retail sales surged in March at the biggest rate in over two years, in what was the latest sign of the US economy's pre-tariff strength.
Why your water bill is an inflation problem that isn't budging
Stock market today: Dow, S&P 500, Nasdaq futures fall as Nvidia reveals costly limits on China exports
The Treasury secretary told Yahoo Finance that the next 90 days should provide 'substantial clarity' on tariffs
Treasury Secretary Scott Bessent tells Yahoo Finance that the US has a 'big toolkit' to deal with bond market volatility
Stocks drift lower as tariff chaos pauses for a day
The chip giant committed to building AI infrastructure in the US, and Trump says he's going to help make it happen.
The fallout from Trump's tariff whiplash hasn't yet pushed investors to shy away from an old habit
Stocks edge higher after back-to-back rallies with Trump's latest tariff moves in focus
BofA's Moynihan says 'we potentially face a changing economy' after highest-ever equities trading haul
The trade war uncovers new economies of scale
Trump is wrecking his own economic agenda
Higher clothing costs from tariffs are coming soon — but not immediately, experts say
Why Tesla, GM, and Rivian will be hurt most by China's critical minerals export ban
Trump says he's 'looking at something' to help car companies with tariffs
Stocks rally for second straight day, while Apple jumps on tech tariff reprieve
The Nasdaq briefly turned red as stocks' relief rally failed to hold in early afternoon trading
Americans are braced for the biggest unemployment rate jump since the pandemic, a New York Fed survey found
Stocks surge as Apple leads way higher after tech's tariff reprieve
Trump's temporary tech tariff respite adds to a growing sense that he has a willingness to listen and bend
Goldman CEO Solomon warns of 'markedly different operating environment' as dealmaking slows
Corporate earnings take center stage amid tariff turmoil: What to know this week
Trump has tariffs, taxes, and the debt ceiling on a collision course for this summer
Trump denies that there was a tariff “exception” for certain electronics announced Friday. (Bloomberg)
Tax day 2025 is coming up. Here’s what to know to file by the deadline.
Commentary: Put the P/E ratio in timeout for now
Market chaos signals 'sell America' trade as Trump tariff whipsaw threatens to upend the US economy's soft landing
Apple was on brink of crisis before tariff concession from Trump (Bloomberg)
Corporate earnings take center stage amid tariff turmoil: What to know this week
The best (and worst) time of year to buy a house
The Trump family is going all-in on crypto projects, from Bitcoin mining to stablecoins (Bloomberg)
How to invest in gold in 4 steps
Changing jobs can disrupt saving for retirement. Here's how to stay on track.
Trump exempts phones, computers, chips from ‘reciprocal’ tariffs (Bloomberg)
Meet Walmart heir Steuart Walton, the most powerful board member you’ve never heard of
The tariff uncertainty isn't getting any better in markets: Chart of the Week
'T-shirts could be the new eggs': Why Trump's chaotic tariff whipsaw is still a huge threat to inflation
Gold notches best week since 2020 amid 'shaken' investor confidence in US
The bond market just had one of its most volatile and unusual weeks in recent memory
Stocks capped a wild week with a surge higher, as the S&P 500 posted its biggest weekly gain since 2023
Stocks swung into rally mode in afternoon trading, with the major indexes all up over 1%. Bond yields pared bigger gains.
The major indexes whipsawed to end a volatile week. Treasury yields surged in signs of more instability in the bond market.
Consumer sentiment craters further as inflation expectations soar to highest since 1981
Dow, S&P 500, Nasdaq slide as China hits US with tariff hike, bank earnings roll in
Johnson & Johnson recently announced a 4.8% increase in its quarterly dividend and released positive Phase 3 clinical data for icotrokinra, an oral treatment for plaque psoriasis. These events occurred alongside solid earnings reports, with a significant rise in net income and earnings per share compared to the previous year. While the company's stock price increased by 6.64% over the last quarter, the broader market also trended upward, climbing 5.9% in the past year. These company developments likely complemented the overall market movements and investor sentiment, rather than diverging from broader trends.
You should learn about the 1 warning sign we've spotted with Johnson & Johnson.
Outshine the giants: these 25 early-stage AI stocks could fund your retirement.
Johnson & Johnson's recent dividend increase and positive Phase 3 clinical data for icotrokinra could significantly bolster investor confidence by enhancing perceptions of future earnings potential and revenue growth. The company's total return, including dividends, was 17.11% over the past five years, indicating steady but moderate financial performance. This is set against the backdrop of a one-year underperformance relative to the US Pharmaceuticals industry's 7% decline.
Looking forward, these announcements could positively influence earnings forecasts, especially with expected boosts from TREMFYA and RYBREVANT within the Innovative Medicine segment. This aligns with strategic acquisitions and product launches that have been projected to grow revenue and expand market footprint. Despite these gains, competition and economic pressures remain considerations, particularly in international markets like China.
Currently trading at US$150, the share price reflects a modest discount to the analyst consensus price target of US$171.11. This implies potential upside and suggests market expectations are still reconciling with Johnson & Johnson's future growth prospects. Revenue and earnings forecasts will likely incorporate these developments, while still being mindful of existing risks such as biosimilar competition and macroeconomic pressures.
Review our historical performance report to gain insights into Johnson & Johnson's track record.
 This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NYSE:JNJ.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Amid recent stock market volatility, the telecom sector offers some respite.  Telecom stocks are relatively stable because of the ubiquity and importance of mobile devices in society, allowing telecoms to produce reliable revenue and free cash flow (FCF).  As a testament to this, while many stocks plunged in the past few weeks, shares of telecom giant AT&T (NYSE: T) hit a 52-week high of $29.03 in April, while rival Verizon Communications (NYSE: VZ) reached its high of $47.35 in March.
US benchmark equity indexes were little changed intraday as companies continued to report financial
Johnson & Johnson on Tuesday reported better-than-expected first-quarter results and lifted its sales forecast for the full year.
Johnson & Johnson forecasts about $400 million in costs this year related to tariffs on medical devices, said Chief Financial Officer Joseph Wolk in an interview.  Wolk said the estimated costs represent a "worst-case scenario" and take into account President Trump’s 90-day pause, China's retaliatory tariffs and the resumption of the U.S. tariffs.  J&J isn't doing anything differently yet in response to tariffs, Wolk added.
We recently published a list of Jim Cramer’s Game Plan: 15 Stocks to Watch. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses. On Friday, Mad Money host Jim Cramer outlined what investors should focus on in the week, especially […]
J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition.
Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year.  The costs will be felt primarily within the company's medical technology unit, which makes a range of medical devices and surgical products.  The most substantial impact comes from tariffs against China and retaliatory tariffs from China, said Joseph Wolk, Johnson & Johnson's chief financial officer, in a conference call with analysts following the company's latest earnings results.
Johnson & Johnson is holding its earnings outlook steady despite President Donald Trump signaling he could put tariffs on the pharmaceutical industry. The administration announced earlier it would conduct an investigation into drug imports. That move is widely seen as a first step toward imposing new levies. Earnings and revenue both beat estimates for the quarter. Johnson & Johnson CFO Joe Wolk joined Bloomberg Open Interest to talk about how tariffs could hit the industry and the drug maker's bottom line.
Fulton Financial (FULT) delivered earnings and revenue surprises of 18.18% and 1.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
We recently published a list of Jim Cramer Sounds the Alarm on China Rhetoric and Dollar Panic Then Analyzes 11 Key Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other key stocks that Jim Cramer analyzes. In his latest appearance on CNBC’s Squawk on the […]
Tip: Try a valid symbol or a specific company name for relevant results
Sign in to access your portfolio



Try again.